VK2735: Reference Overview and Reconstitution Notes

VK2735 is a research compound being studied for how it affects metabolism and body weight. It has not been approved by the FDA for any use.

VK2735

What it is

VK2735 is a man-made peptide (a short chain of amino acids, which are the building blocks of proteins) developed by Viking Therapeutics. It is a dual agonist, meaning it activates two different receptors at the same time. Think of receptors as docking stations on the surface of cells. The two receptors it targets are the glucagon-like peptide-1 (GLP-1) receptor and the glucose-dependent insulinotropic polypeptide (GIP) receptor. Both are involved in blood sugar control and appetite after a meal.

VK2735 works in the same general way as a compound called tirzepatide. Both belong to a class called dual incretin receptor agonists (incretin hormones are gut hormones released after eating that help regulate blood sugar). VK2735 is being studied in two forms: a once-weekly injection and a pill taken by mouth.

Key point: VK2735 is an investigational dual GLP-1/GIP receptor agonist studied for its dual action on key metabolic and weight-regulation pathways.

Research context and categorization

VK2735 falls under the metabolic and weight-regulation research category. Metabolism is how the body turns food into energy. Because VK2735 activates two receptor pathways at once, researchers study how it may affect appetite signals, blood sugar release, how quickly the stomach empties, and body weight.

In the published Phase 2 VENTURE study and follow-up trial reports, the injectable form was studied for weight reduction over a short treatment period. A separate pill form has also been studied in the same context.

These uses are investigational. VK2735 has not completed the full review process needed for regulatory approval. Nothing described in trial reports should be treated as a confirmed or approved outcome. The compound is still in development, and any research framing here reflects what it is studied for, not established benefits.

Status

• Regulatory status: Research-only and investigational. As of 2026, VK2735 is not FDA-approved for any use. It is still in clinical trials and is advancing into Phase 3 development (the third and largest stage of human testing before approval can be sought).
• Sport status: VK2735 is not listed by name on the WADA Prohibited List (the World Anti-Doping Agency's list of banned substances in sport). It is an investigational compound, not a named banned substance. However, the broader class of GLP-1/GIP receptor agonists has received ongoing attention from WADA under the category of hormone and metabolic modulators, and the status of a compound class can change from year to year. Anyone competing in a tested sport should check the current WADA Prohibited List and Monitoring Program directly, rather than relying on assumptions about the class.

Reconstitution notes (general)

Research peptides are often sold as a lyophilized (freeze-dried) powder. To use the powder at a lab bench, you add bacteriostatic water (water with a small amount of preservative added to stop bacteria from growing) to the vial. This process is called reconstitution. Think of it like dissolving a bouillon cube in water: the dry solid becomes a liquid solution.

The concentration of the resulting solution depends on how much water you add. The math is simple: concentration equals the milligrams of peptide in the vial divided by the milliliters of water added. Here is how that looks:

• A 10 mg vial reconstituted with 2 mL yields 5 mg/mL.
• A 10 mg vial reconstituted with 1 mL yields 10 mg/mL.

A reconstitution calculator is available at peptide calculator to work out the concentration for a given vial size and water volume.

Dilution and handling notes (compound-specific)

The research-supply form of VK2735 is typically a lyophilized (freeze-dried) powder, most often in vials of 5 mg to 15 mg, with 10 mg being the most common size.

Note that VK2735 is also being developed as an oral tablet. That tablet is a formulated pharmaceutical product and is not the same thing as a research vial. The reconstitution notes here apply only to lyophilized powder, not to any oral form.

Reconstitution instructions

For the injectable powder form, a common approach is to add 1 mL to 2 mL of bacteriostatic water to a 10 mg vial. Using less water gives a higher concentration and a smaller volume to measure. Using more water gives a lower concentration that is easier to measure precisely.

Peptides in the incretin class generally dissolve easily and produce a clear, colorless solution. Follow these steps to reconstitute safely:

1. Add the water slowly down the inner wall of the vial rather than directly onto the powder.
2. Swirl or gently roll the vial. Do not shake vigorously, because hard shaking can create foam and cause peptide molecules to clump together (called aggregation), which can reduce quality.
3. If a concentrated solution looks slightly hazy or is slow to clear, let it sit and swirl gently.

Persistent cloudiness, floating particles, or any color change means the solution should not be used.

Handling and storage

To keep a reconstituted solution in good condition, follow these storage steps:

• Store the reconstituted solution in a refrigerator at 2 to 8 C and keep it away from direct light.
• Wipe the rubber stopper with an alcohol swab before each withdrawal.
• Label the vial clearly with the date it was mixed.
• A reconstituted peptide handled cleanly can generally be used within a four-week refrigerated window.
• Discard the vial right away if the contents become cloudy or discolored, or if you see floating particles.

Related reading

• ACE-031
• Amycretin
• ARA-290
• How Reconstitution Works
• How Long Does a Reconstituted Vial Last?

Tools and supplies

• peptide calculator
• Bacteriostatic Water 30 ml
• Gansulin Metal Reusable Pen
• 3 ml Glass Cartridges (10-pack)
• Complete Starter Kit

Reminder: research and educational reference only. Preppin Peppers sells hardware and materials, not peptides. Not medical, dosing, or health advice, not evaluated by the FDA, and not intended for human or animal use.

Frequently asked questions

What is VK2735 and how does it work?

VK2735 is a man-made dual GLP-1/GIP receptor agonist peptide that activates both glucagon-like peptide-1 and glucose-dependent insulinotropic polypeptide receptors, similar to tirzepatide, studied for metabolic pathways.

What is the regulatory status of VK2735?

VK2735 is research-only and investigational, not FDA-approved for any use as of 2026, currently advancing into Phase 3 clinical trials.

What is peptide reconstitution in research?

Reconstitution is adding bacteriostatic water to lyophilized peptide powder to create a solution for lab research, with concentration determined by the volume of water added.

What the research community gets wrong about VK2735

A few ideas about VK2735 come up again and again at the bench. Here is what the details actually say for anyone handling vials.

• The research powder is not the oral tablet. VK2735 has been studied both as a subcutaneous form and as an oral tablet, and it is easy to mix the two up. A lyophilized powder in a research vial is a different material from a formulated tablet, so notes written for one do not carry over to the other.
• Sharing receptor targets does not mean it handles like tirzepatide. VK2735 and tirzepatide are both described as GIP/GLP-1 dual agonists, but that says nothing about how a given lot dissolves, how clear the solution runs, or how it holds up in the fridge. Treat each compound, and each lot, on its own.
• The number on the label is nominal, not a guarantee of peptide mass. A vial marked 10 mg tells you the intended fill, not the exact peptide content, which can shift with purity, water, and counterion (the salt paired with the peptide). Concentration math based only on the label can read higher than what is really in the vial.
• A clear solution is not proof the peptide is intact. Peptides can break down without any change you can see. Clarity, or an unchanged look, does not confirm that the molecule is still whole, so appearance alone is a weak check.
• "Advancing in trials" is not "approved." As of 2026 VK2735 is investigational and not FDA approved for any use. Study reports describe what it is being tested for, not a settled result, and none of that changes how a research sample should be logged and stored.

From our bench: If you reconstitute a VK2735 research vial, log the plain facts of that prep. Note the vial size on the label, the exact volume of bacteriostatic water you added, how long the solution took to run clear, and whether it stayed clear over the following days in the fridge. Send us your real numbers and observations. We will add anonymized bench notes here so handlers can compare against actual data instead of guesswork.

Sources

1. Bacteriostatic Water for Injection, USP , FDA/DailyMed label (0.9% benzyl alcohol)
2. Duerkop et al., Biotechnol J 2018 , Impact of Cavitation, High Shear Stress and Air/Liquid Interfaces on Protein Aggregation
3. Sigma-Aldrich (Merck) , Handling and Storage Guidelines for Peptides and Proteins
4. Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring), 2026 (PubMed, PMID 41508550)
5. Phase 2 Dose Finding Study of VK2735 Oral Formulation for Weight Management (VENTURE), Viking Therapeutics (ClinicalTrials.gov NCT06828055)